In recent research, the salivary microbiome of nondiabetic individuals, treatment-naïve diabetic patients, and those treated with metformin or combined insulin therapy were compared, highlighting significant microbial diversity changes linked to the onset and treatment of T2DM. The gene discussed is INS; the disease is type 2 diabetes mellitus.